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Background: Inhibition of pathogenic protein 
aggregation by small molecules is poorly 
understood.
Results: Aggregation inhibitors alter the free 
energy landscape of a relevant fragment of 
Alzheimer's amyloid-β protein in subtle but 
complex fashion.
Conclusion: Intrinsic disorder of disease proteins 
persists at the level of binding small molecules.
Significance: Hallmark characteristics and 
efficacy of inhibitors can be reconciled with lack 
of specificity.
SUMMARY
In  recent  years,  an  increasing  number  of 
small  molecules and short peptides have been 
identified  that  interfere  with  aggregation 
and/or  oligomerization  of  the  Alzheimer's  β-
amyloid  peptide  (Aβ).  Many  of  them possess 
aromatic  moieties  suggesting  a  dominant  role 
for those in interacting with Aβ  along various 
stages of the aggregation process. In this study, 
we attempt to elucidate whether interactions of 
such aromatic inhibitors with monomeric Aβ12-
28 point to a common mechanism of action by 
performing  atomistic  molecular  dynamics 
simulations at equilibrium. Our results suggest 
that,  independently  of  the  presence  of 
inhibitors,  monomeric  Aβ 12-28 populates  a 
partially  collapsed  ensemble  that  is  largely 
devoid  of  canonical  secondary  structure  at 
300 K  and  neutral  pH.  The  small  molecules 
have different affinities for Aβ12-28 that can be 
partially  rationalized  by  the  balance  of 
aromatic and charged moieties constituting the 
molecules.  There are no predominant binding 
modes,  even  though  aggregation  inhibitors 
preferentially  interact  with  the  N-terminal 
portion  of  the  fragment  (residues  13-20). 
Analysis of the free energy landscape of Aβ12-28 
reveals  differences  highlighted  by  altered 
populations  of  a  loop-like  conformer  in  the 
presence  of  inhibitors.  We  conclude  that 
intrinsic disorder of Aβ  persists at the level of 
binding  small  molecules,  and  that  inhibitors 
can significantly alter properties of monomeric 
Aβ  via multiple routes of differing specificity.
Alzheimer's  disease  (AD)  is  the  most  common 
form of  dementia  in  the  elderly.  Strong genetic, 
physiological  and biochemical  evidence suggests 
that the β-amyloid peptide (Aβ) plays a key role in 
the  pathogenesis  of  AD  (1).  Neuropathological 
changes  in  the  brain  of  AD  patients  include 
neuronal  death in the regions related to memory 
and cognition, as well as the abnormal presence of 
intra-  and  extracellular  protein  aggregates  (2,3) 
known  as  neurofibrillary  tangles  and  amyloid 
plaques.  They are the final  results  of  a complex 
series  of  oligomerization  and  polymerization 
events  that  typically  follow  a  nucleation-
dependent  mechanism  (4).  The left-hand side  of 
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Disordered binding of small molecules to Aβ12-28
Fig. 1 shows a cartoon schematic illustrating a few 
steps along the pathway of Aβ fibrillization. The 
nucleus  is  typically  assumed  to  be  a  larger 
oligomer (4-6), and the nucleation event itself may 
be  linked  to  a  critical  structural  transition 
involving tertiary and quaternary contacts within 
such  an  oligomer  or  protofibril  (5).  Subsequent 
monomer  addition  appears  to  be  the  dominant 
mode of fibril elongation (4). Peptide aggregation 
processes have been studied in depth with several 
experimental  (7,8) and  computational  techniques 
(9-12),  but  often  remain  poorly  understood. 
Although little is known on the link between the 
aggregation  mechanism  and  neurotoxicity  (13), 
experimental  evidence  indicates  that  soluble 
oligomers and fibrillar  precursors of Aβ may be 
the dominant neurotoxic species (14).
In  recent  years,  increasing  evidence  points  to  a 
link between disease and disorder, specifically, the 
functions and properties of intrinsically disordered 
proteins  (IDPs)  and polypeptide  stretches  within 
proteins (IDRs)  (15,16). The ensembles explored 
by such sequences, which are estimated to make 
up  about  20%  (17) of  eukaryotic  genomes,  are 
highly diverse and devoid of long-lived, “folded” 
conformers  (18). Extensive analyses have shown 
that  simple  sequence-based  classifiers  such  as 
mean hydrophobicity or net charge can be used to 
distinguish folded proteins from IDPs (19). Aβ40/42 
belongs to the class of collapsed-disordered IDPs 
(20) on  account  of  its  low net  charge  and  high 
hydrophobicity  (21,22).  IDPs  often  attain  partial 
order  upon functional  or  deleterious  interactions 
with  folded  proteins  or  with  other  IDPs  (23). 
Indeed, pathogenic self-assembly can be viewed as 
a  specific  variant  of  the  latter  case.  Given  that 
collapse and aggregation are guided by the same 
driving  forces,  it  is  perhaps  not  surprising  that 
IDPs such as Aβ or polyglutamine are associated 
with protein aggregation diseases (24-26).
Inherently, structural drug design aimed at finding 
compounds  that  interfere  with  an  IDP-mediated 
process faces the challenge that structural targets 
emerge only later  on the pathway.  Nevertheless, 
the  identification  and  detailed  biophysical 
characterization of small molecules that modulate 
Aβ peptide self-assembly are expected to generate 
new lead  candidates  for  clinical  studies.  Several 
therapeutic  strategies  have  been  suggested  for 
blocking  key-steps  in  the  amyloid  aggregation 
process,  including  the  direct  inhibition  of 
aggregation  by  using  either  peptides  or  small 
molecules  (27-38).  As  an  example,  indole 
derivatives inhibited fibril formation of Aβ peptide 
(39,40) and lysozyme  (41). Anthraquinones were 
shown to be inhibitors of tau protein (42) and Aβ40 
aggregation  (37), and  hybrid  molecules  bearing 
both indole and quinone rings have been effective 
in  the  recovery  of  a  fly  model  of  AD  (43).  In 
addition, antioxidants, e.g., resveratrol (44,45) and 
epigallocatechin-3-gallate (46),  and  non-steroidal 
anti-inflammatory  molecules  such  as  naproxen 
(47,48) revealed  new biological  activities  in  the 
inhibition of amyloid aggregation.
Recent  X-ray  microcrystallography  (49,50) and 
solid-state  nuclear  magnetic  resonance  (NMR) 
spectroscopy (51) studies have provided atomistic 
information  on  the  interactions  between  small-
molecule  binders  and  amyloid  fibrils. Fig.  1 
illustrates why this may be less relevant than the 
interactions  of  inhibitors  with  soluble  peptide 
species.  In  essence,  compounds  that  specifically 
bind fibrils (step VI in Fig. 1) may destabilize the 
latter  (52),  but  will  have  little  impact  on  the 
association and conformational equilibria prior to 
nucleation  (steps  I  and  II).  An  alternative 
mechanism of inhibition could be a depletion of 
nucleation-competent  (53) and/or toxic oligomers 
(54) either  by  stabilization  of  low  molecular 
weight  species  such  as  monomers  and  dimers 
(steps  III  and  IV) or  of  larger  off-pathway 
oligomers (step V). Given the disordered nature of 
the binding partner  (55), it is quite reasonable to 
stipulate that small molecules can have differential 
effects for all indicated steps including the known 
ability to increase the rate of fibrillization (56,57). 
The complexity is exacerbated by the fact that the 
dominant  pathways  may shift  in  dose-dependent 
manner. Fig. 1 implies that studies of the binding 
equilibria  of  monomeric  Aβ with  inhibitors  can 
yield insight regarding the molecular mechanisms 
of inhibition.
Here,  we  use  molecular  dynamics  (MD) 
simulations  to  analyze  ten  different  small-
molecule inhibitors of Aβ peptide aggregation, and 
focus on their influence on the free energy surface 
of  monomeric  Aβ12-28.  The  choice  of  studying  a 
truncated construct is motivated by three reasons. 
First  and foremost,  it  is  important  to  be able  to 
obtain  statistically  reliable  simulation  results. 
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Conformational  transitions  in  the  full  length 
alloforms can occur on timescales that exceed the 
currently accessible regime (58). Second, residues 
12-28 highlight  the  role  of  the  so-called  central 
hydrophobic  cluster,  CHC  (59),  residues  17-21, 
that  is  often  assumed to be critical  in mediating 
peptide-inhibitor  (60) as  well  as  peptide-peptide 
interactions  (61).  By discarding the hydrophobic 
C-terminus, our simulations allow us to delineate 
the possible specific roles played by the residues 
in  this  stretch.  Truncation  of  residues  1-11  is 
justified by experimental (62) and simulation (21) 
studies that  show this  segment to  be completely 
unstructured. Third, segment 12-28 could be used 
in high enough concentrations suitable for solution 
NMR spectroscopy experiments  (43),  because  it 
has  lower  oligomerization  and  fibrillization 
propensities  than  Aβ40  and  Aβ42.  This  implies 
that it will be easier to derive testable hypotheses. 
We use the cut-based free energy profile (cFEP) 
method  (63) to  identify the  metastable  states  of 
monomeric Aβ12-28 and the change of their relative 
stability upon inhibitor binding.
This  study  was  inspired  by  the  following 
questions:  How does  the  free  energy surface  of 
monomeric Aβ12-28 change in the presence of small 
molecules  that  are  known  to  interfere  with 
oligomerization  and/or  fibril  formation?  Do 
different  inhibitors  of  Aβ peptide  self-assembly 
share  similar  interaction  motifs  with  monomeric 
Aβ12-28? Is there a major binding mode? The MD 
simulation results indicate that monomeric Aβ12-28 
is largely disordered with and without inhibitors. 
The  most  frequent  interaction  motifs  are  similar 
for  different  inhibitors.  There  is  no predominant 
binding  mode  because  Aβ12-28 is  highly flexible, 
and its plasticity is marginally influenced by the 
small-molecule inhibitors. An analysis of binding 
frequency  and  the  enhancement  of  a  specific, 
otherwise  transiently  populated  conformation  of 
Aβ12-28 in  the  presence  of  inhibitors,  suggests  a 
complex interplay of interfacial effects, trends that 
can  be  mapped back to  simple  physicochemical 
properties  of  the  primary  sequence,  and  lastly 
highly specific effects that require elucidation by 
atomistic simulations. 
EXPERIMENTAL PROCEDURES
Implicit solvent simulations. Simulations were 
performed with the CHARMM program (64). The 
Aβ12-28 peptide and inhibitors were modeled using 
the  united  atoms  CHARMM  PARAM19  force 
field with its  default  truncation scheme for non-
bonded interactions (cutoff  of  7.5 Å). Parameters 
for 1,4-napthoquinon-2-yl-L-tryptophan (NQTrp), 
anthracene, and 9,10-anthraquinone were derived 
as  reported  in  (37,43).  Protonation  states  of 
titratable residues were considered at neutral pH. 
In particular, the His side chains of Aβ12-28 and β-
Ala-His were neutral (protonated at the Nδ), while 
the  charges  of  the  Asp/Glu  and  Arg/Lys  side 
chains  were  -1  and  +1  electronic  units, 
respectively. The net charge of the Aβ12-28 segment 
is zero as there are two positively charged residues 
(Lys16  and  Lys28)  and  two  negatively  charged 
residues  (Glu22 and Asp23),  and the N- and C-
terminus  were  capped  with  acetyl  and  N-
methylamide  groups,  respectively.  The 
electrostatic  contribution  to  solvation  was 
accounted for by using FACTS  (65), an efficient 
generalized Born implicit solvent model based on 
the fully analytical evaluation of the volume and 
spatial symmetry of the solvent that is displaced 
from  around  a  solute  atom  by  its  neighboring 
atoms.  The  non-polar  contribution  to  the  total 
effective solvation energy was approximated by a 
term proportional to the solvent-accessible surface 
area  of  the  solute  using  a  surface  tension-like, 
multiplicative  parameter  of  7.5 cal mol-1Å-2. 
Starting conformations were prepared by placing 
fully extended Aβ12-28 in the presence or absence of 
a single molecule of the inhibitor in the simulation 
box  (1:1  concentration  ratio).  Simulations  were 
carried out  with periodic  boundary conditions  at 
fixed peptide concentration of  ca.  2.5 mM (87 Å 
cubic  simulation  box)  using  the  Langevin 
integrator at low friction (coefficient of 0.15 ps-1) 
and at a temperature of 300 K. Using a time step of 
2 fs,  for  each  system  we  performed  three 
independent runs of 5 µs each.
Explicit solvent simulations. Using GROMACS 
v4.5.3  (66),  capped  Aβ12-28 was  simulated  in  a 
cubic  box  of  60 Å  side  length  in  the  NPT 
ensemble.  The  velocity  rescaling  thermostat  of 
Bussi  et  al.  (67) was  used  to  keep  a  constant 
temperature of 310 K, while an ambient pressure 
of  1 bar  was  maintained  using  the  Parrinello-
Rahman  barostat  (68).  The  peptide  was 
represented with the CHARMM27 all-atom force 
field including CMAP corrections  (69). The bath 
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consisted  of  a  solution  of  ca.  150 mM  NaCl  in 
TIP3P water  (70).  Electrostatic interactions were 
modeled by the particle-mesh Ewald method (71). 
All real-space interactions were truncated at 12 Å. 
Neighbor  lists  were  recalculated  every  5  steps. 
LINCS  (72) was  used  to  constrain  all  bonds 
involving  hydrogen  atoms  to  their  parameter-
derived  values.  The  time  step  was  2 fs,  and  we 
obtained  three  independent  simulations  starting 
from random,  extended  structures  that  each  are 
380 ns  in  length,  the  first  20 ns  of  which  we 
discarded as equilibration. Preliminary analyses of 
secondary  structure  propensities  or  contact 
patterns revealed that given the reduced amount of 
sampling  and  increased  friction  statistical 
convergence for the majority of readouts could not 
be obtained. Therefore, data from explicit solvent 
simulations are only included in Fig. 2.
cFEP analysis. The 750,000 snapshots of each 
system were clustered by the Leader algorithm as 
implemented in Wordom (73) using the Cα atoms 
of  residues  14-24 and a  threshold of  1.0 Å.  The 
cut-based  Free  Energy  Profile  (cFEP)  (63) 
technique was used to identify metastable states of 
monomeric Aβ12-28 and the change of their relative 
stability upon inhibitor binding. The input for the 
cFEP calculation is the network of conformational 
transitions,  which  is  derived  from  the  direct 
transitions  between  clusterized  snapshots  (nodes 
of the network) sampled at a given time interval 
(20 ps here) along the MD simulations. For each 
node, nodes are partitioned into two groups using 
the values of the mean first passage times (mfpt) 
to  the  reference  node  to  define  a  cut.  The  free 
energy is related to the maximum flow across the 
cut  and  approximated  as  ∆G=-kTln(ZAB),  where 
ZAB is  the  partition  function  of  the  mfpt-based 
cutting  surface  (for  further  details  refer  to  Ref. 
(63)). The result is a one-dimensional profile along 
a  reaction  coordinate  (the  relative  partition 
function,  termed ZA/Z) that  preserves  the barrier 
height between the free energy basins.
RESULTS AND DISCUSSION
The  following  analysis  concerns  the  FACTS 
implicit  solvent  MD  simulations  at  300 K.  The 
reference system is  monomeric  Aβ12-28 while  the 
simulations  with  inhibitors  contained  a  single 
inhibitor  molecule  along  with  Aβ12-28 at  a  final 
concentration  of  ca.  2.5 mM.  Each  of  these  11 
systems was simulated for a total of 15 µs. If not 
stated  otherwise,  the  statistical  significance  (i.e., 
convergence)  of  the  simulation  results  was 
assessed by computing min/max errors from block 
averages over three or six blocks. 
Monomeric  Aβ12-28 is  partially  collapsed  and 
disordered. Visual  inspection  of  the  trajectories 
showed that  Aβ12-28 does  not  attain any specific, 
long-lived  structure  akin  to  a  folded  ensemble. 
Conformational  transitions  are  rapid and yield  a 
disordered ensemble. To quantitatively assess the 
overall  polymeric  state  of  the  Aβ peptide,  we 
computed  the  scaling  of  internal  distances  with 
sequence spacing as well as the angular correlation 
function as described in previous work  (74). The 
data in Fig. 2 indicate that - independently of the 
presence of an inhibitor - the peptide populates a 
partially collapsed ensemble. Inhibitors appear to 
be able to cause both compaction and swelling of 
Aβ12-28,  but  many  of  the  differences  are 
insignificant. For fully globular species one would 
expect the internal scaling plot to yield a plateau 
(75) similar  to  what  we  observed  for  the  full 
length  alloforms  (21),  while  the  theoretical 
prediction  for  a  chain  in  a  good  solvent  is 
significantly  more  expanded.  As  described  in 
Experimental  Procedures,  we  performed 
calculations in explicit solvent of the free system. 
These  data  are  shown  as  well  in  Fig.  2.  They 
crudely illustrate  similarity between implicit  and 
explicit  solvent  ensembles  (Panel  A),  and 
simultaneously demonstrate the difficulty to obtain 
converged  explicit  solvent  results  even  for  low-
dimensional  readouts  such  as  the  angular 
correlation function (Panel B).
To demonstrate  dominant  disorder  in  Aβ12-28,  we 
show in Fig.  3 the cut-based free energy profile 
(cFEP) of the free system. The profile is devoid of 
significant free-energy barriers, and dominated by 
a large entropic basin composed of conformations 
that  lack  canonical  secondary  structure.  The 
remaining 30-40% of the ensemble is made up by 
various  enthalpic  basins,  and  cartoon 
representations  of  representative  snapshots  have 
been  added  for  illustration  purposes.  Taken 
together,  these  results  indicate  that  Aβ12-28 is 
unstructured  at  physiological  conditions  in  the 
absence  of  small-molecule  inhibitors  of 
aggregation. Similar observations hold for Aβ12-28 
in the presence of any of the aggregation inhibitors 
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(see Figs. S2-S11 in the Supplemental Data). The 
lack  of  a  predominant  structure  and  the  small 
height of barriers for the ensemble of monomeric 
Aβ12-28 are  consistent  with  data  from  NMR 
spectroscopy experiments (76,77).
Main  interactions  between  monomeric  Aβ12-28 
and  aggregation  inhibitors. Table  1 shows 
estimates  for  how  frequently  each  inhibitor  is 
"bound"  to  the  peptide  in  the  simulations.  To 
resolve which parts  of  Aβ12-28 inhibitors bind to, 
Fig.  4  shows  intra-  and  intermolecular  contact 
maps for the free system as well as for simulations 
in the presence of inhibitors. The most frequently 
observed intermolecular contacts are shared by all 
inhibitors,  and  involve  mainly  the  N-terminal 
segment (residues 13-20). With the exception of β-
Ala-His that largely remains dissociated, the large 
hydrophobic  side  chains  of  Phe19  and  Phe20 
constitute the site of highest interaction probability 
in all cases. It is interesting to note that the larger 
peptidic inhibitors appear to  show more specific 
contact  patterns  than  for  example  anthracene  or 
9,10-anthraquinone.  This  is  consistent  with  the 
complexity  of  the  interfaces  presented  by  each 
molecule:  anthracene  is  a  completely 
homogeneous  tricyclic  molecule,  whereas  the 
tetrapeptides  have  three  different  aromatic 
moieties (two of which have polar sites),  one or 
two formal charges, and a mainly rigid spacer. The 
segment  24-28  appears  to  be  largely  inert  to 
inhibitor  binding  consistent  with  the  fact  that 
residues in this region do not feature prominently 
in sequence analyses (62,78,79), mutation (80), or 
fragment binding studies (61) as being responsible 
for amyloid formation. While this is also true for 
the  N-terminal  residues  we  truncated,  the  same 
cannot be said for C-terminal residues 29-40/42. A 
priori, we have no reason to assume that inhibitors 
would not bind to this portion of Aβ (see Fig. 1). 
However, the questions in this work center around 
the  interaction  of  aromatic  inhibitors  with  the 
central hydrophobic core as the suspected site of 
highest  affinity  (81).  Given  that  several  of  the 
inhibitors  have  significant  impact  on 
oligomerization and fibrillization  (36,43)  even at 
sub-equimolar  concentrations  ratios,  this  may 
represent a reasonable simplification. 
We can attempt to explain the interaction patterns 
within the confines of the employed computational 
model  by decomposing system energetics.  As an 
example,  we  focus  on  NQTrp,  which  has  the 
highest affinity for Aβ12-28 in the MD simulations 
(see Table 1) and is also one of the most  potent 
inhibitors  of  Aβ peptide  aggregation  in 
experiments  (43). In Fig. 5, the decomposition of 
the  dominant  term of  the  intermolecular  energy 
into  contributions  from  individual  pairs  of 
functional  groups  shows  that  the  two  aromatic 
moieties of NQTrp make favorable van der Waals 
interactions with the entire N-terminal  stretch of 
the peptide (residues 13-20). In addition, binding 
appears  to  feature  favorable  electrostatic 
interactions involving the (charged) carboxy group 
of  NQTrp  and  peptide  residues  12-16,  which 
possess  a  wealth  of  polar  hydrogens  (His13, 
His14,  Gln15,  and  Lys16).  This  can  be  inferred 
indirectly  from  the  favorable  van  der  Waals 
interactions  between  the  carboxy group  and  the 
peptide.  We  did  not  consider  electrostatic 
interactions here because of effective multi-body 
terms  preventing  pairwise  decomposition.  In 
general, good correspondence is seen between the 
interaction  energy  matrix  and  contact  maps 
indicating that binding is largely enthalpic. This is 
expected  in  particular  given  that  entropic 
contributions to ligand binding stemming from the 
solvent  are  accounted  for  implicitly  in  the 
continuum model. 
It  is  possible to  rationalize the relative affinities 
for Aβ12-28 to the ten inhibitors by focusing on the 
three  main  contributions,  i.e.,  unfavorable 
desolvation  of  hydrophilic  moieties,  favorable 
burial of hydrophobic moieties, and favorable van 
der Waals interactions (see Tables 1 and S2). The 
total polar desolvation penalty ranges from 1 to 5 
kcal/mol and scales roughly with the size of the 
inhibitor. No persistent salt bridges are formed and 
the contribution is generally unfavorable. Burial of 
hydrophobic  surface  contributes  favorably.  This 
term  correlates  with  the  number  of  aromatic 
moieties present on the inhibitor. Lastly, dispersive 
interactions  between  inhibitor  and  Aβ12-28 
contribute  the  bulk  of  the  favorable  effective 
binding energy.  It  appears as if  this  contribution 
becomes less predictable with increasing numbers 
of hydrophobic moieties present  on the inhibitor 
(e.g, NQTrp has a significantly more favorable van 
der  Waals  contribution  than  either  Tyr-Aib-Trp-
Phe or Tyr-Pro-Trp-Phe despite possessing fewer 
aromatic  moieties).  The  computed  effective 
binding energies reproduce the rank order seen in 
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Table 1 reasonably well. Two exceptions shall be 
mentioned:  The  first  is  Tyr-Pro-Phe-Phe,  which 
appears  to  incur  a  significant  entropic  penalty 
upon binding that is consistent with a significantly 
more structured free energy surface of Aβ12-28 in 
the  presence of  Tyr-Pro-Phe-Phe (see Fig.  S7 in 
Supplemental  Data).  On the contrary,  anthracene 
exhibits high affinity despite its modest effective 
binding energy.  Here, the entropic penalty at the 
inhibitor level is essentially zero (rigid molecule), 
and the contact map indicates the most degenerate 
binding (see Fig. 4) suggesting a minimal entropic 
penalty at the peptide level as well. 
Returning to Fig. 4, we note that inhibitor binding 
has an impact on intramolecular contacts of Aβ12-28 
as  well.  While  the  contact  maps  continue  to 
indicate degenerate long-range interactions within 
the  peptide,  the  presence  of  inhibitors  seems  to 
enhance contacts between residues 12-15 and 21-
26 (marked in the plots). This is a relatively weak 
effect that is observed for all inhibitors but β-Ala-
His, and most prominently for NQTrp. It points to 
the  ability  of  molecules  composed  of  similar 
building  blocks  to  exert  a  generic  effect  on  the 
conformational  properties  of  Aβ12-28,  and  this  is 
discussed next.
Changes  in  the  free  energy surface  of  Aβ12-28 
upon inhibitor binding. The DSSP  strings in Figs. 
S1-S11  in  Supplemental  Data  suggest  that  the 
overall secondary structure content of Aβ12-28 is not 
strongly  altered  in  the  presence  of  inhibitors 
compared to the free system (Fig. 3). Fig. 6 shows 
that the inhibitors generally increase the content of 
loop, bend, and turn conformations in the segment 
13-23  at  the  expense  of  regular  secondary 
structure, particularly of helix. These changes are 
qualitatively similar for all inhibitors. As expected, 
the low affinity compounds  β-Ala-His and  DTrp-
Aib exhibit only weak effects. The same is true for 
anthracene  despite  its  affinity  being  the  second 
highest  (Table  1).  This  is  consistent  with  the 
entropic binding mode described above. Over the 
same  sequence,  β-secondary  structure  is 
significantly  enhanced  only  in  the  presence  of 
DTrp-Aib  and  Tyr-Pro-Phe-Phe.  In  contrast  to 
residues 13-23, there are negligible differences for 
residues 24-28, which is consistent with the lack 
of interactions between the inhibitors and the C-
terminal  segment  of  Aβ12-28 (see  Fig.  4).  The 
effects  are  overall  subtle  and  confirm  the 
prevalence of disorder in binding. 
As  noted above,  the  presence  of  inhibitors  does 
seem  to  enhance  intramolecular  Aβ12-28  contacts 
between  residues  12-15  and  21-26  (see  Fig.  4). 
This points to the potential of inhibitors to alter the 
free  energy  surface  of  Aβ12-28 in  a  manner  that 
cannot  be  captured  clearly  by  evaluating 
ensemble-averaged  readouts  like  secondary 
structure  propensities.  Cut-based  FEPs  represent 
an  appropriate  way  to  condense  trajectory 
information  and  to  show  approximately  the 
distributions of barriers and basins. In Fig. 3, free 
Aβ12-28 exhibited  no  predominantly  populated 
conformation. When clustering data using the
 
Cα 
atoms  of  residues  14-24,  the  most  populated 
conformer  corresponds  to  a  straight  helical 
structure  (see  Fig.  7)  with  a  disordered  C-
terminus.  The  entire  helical  basin  encompasses 
partially  helical  as  well  as  completely  helical 
structures that constitute a total statistical weight 
of  about  10%. It  is  separated by a  wide barrier 
region  comprised  of  minor  basins  with  partially 
helical  states  (population  of  about  10%)  from a 
broad entropic basin (70%). The latter consists of 
fluctuating  conformers  devoid  of  regular 
secondary  structure  content.  Figs.  S2-S11  in 
Supplemental Data show the same type of data for 
simulations  in  the  presence  of  inhibitors.  In  all 
cases,  a  large  entropic  basin  has  the  largest 
statistical weight indicating that inhibitors are not 
able to lock Aβ12-28 into a specific conformation. 
There  are  changes,  however,  to  the  relative 
weights  of  ordered  conformers.  In  particular,  a 
basin is increasingly populated that corresponds to 
a  compact  structure  characterized  by  a  specific 
loop conformation spanning residues 14-24. It  is 
stabilized  (see  Fig.  7)  by  the  formation  of  a 
hydrogen-bonded network of side chains including 
Asp23,  His13  and  either  Gln15  or  His14.  Its 
statistical weight for each inhibitor is summarized 
in Table S1 in Supplemental Data and ranges from 
ca. 2 to 20%. Given that the population of the loop 
is lowest for the free system and in the presence of 
largely  inert  β-Ala-His,  and  that  it  is  only 
transiently populated in either case (see Fig. S12-
S13 in Supplemental  Data),  one may ask how a 
specific  Aβ12-28 conformation  can  be  universally 
enhanced by other inhibitors in the absence of a 
specific binding mode. 
The  answer  is  that  the  inhibitors  provide  an 
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Disordered binding of small molecules to Aβ12-28
additional  non-aqueous interface,  i.e.,  they allow 
patterns of sequestering residues from solvent to 
change.  Normalized  by  their  propensity  to  bind 
Aβ12-28,  the  indole-containing  inhibitors  NQTrp 
(see Table S1 in Supplemental Data) and DTrp-Aib 
exert the largest effect in this regard. Indole groups 
have been heavily implicated in  Aβ aggregation 
inhibitor  design  (39),  and were also analyzed  in 
systematic fashion as inhibitors of hen egg white 
lysozyme  aggregation  (41).  Interestingly,  the 
inhibitor  is  not  required to  interact  directly with 
the polar residues mentioned, but can act indirectly 
or  allosterically.  Such a  mechanism of  action  is 
entropically  favored  on  account  of  the  peptide's 
high intrinsic flexibility (this is true for example 
for  DTrp-Aib  as  seen  in  see  Fig.  S14  in 
Supplemental  Data).  However,  Fig.  S14  also 
shows  a  counterexample:  Direct  binding  of 
anthracene to the side chains of Asp23 and Gln15 
occurs  with  greater  frequency  than  binding  in 
general, and population of  the loop conformer in 
the absence of binding is  essentially identical  to 
that seen for the free system. These data resemble 
a  conformational  selection  mechanism described 
in  binding  equilibria  of  intrinsically  disordered 
proteins (82). 
An interfacial effect as described is intriguing as it 
allows  for  an  explanation  as  to  why  so  many 
different  inhibitors,  which  share  some  structural 
hallmarks have been characterized (83,84). If one 
compares  the  requirements  for  small  molecule 
design in enzyme inhibition to that of inhibition of 
oligomerization  and  fibrillization,  one  would  be 
forced to conclude that the intrinsic disorder of the 
target translates to the inhibitor level. This could 
imply that  "poly-functional"  moieties  combining 
largely hydrophobic parts with polar sites are well-
suited  to  bind  disordered  Aβ.  Disordered 
interactions  of  such  poly-functional  units  with 
peptide moieties may also explain why mutation 
studies  have failed to  establish the necessity for 
aromatic residues Phe19 and Phe20 in Aβ to be 
present  for  aromatic  inhibitors  of  the  general 
flavor tested here to be effective (85).
It should be noted that the partial desolvation of a 
charged  moiety  (Asp23)  may  raise  questions 
toward the accuracy of the computational model in 
use.  We wish  to  emphasize  that  we  assign little 
importance  to  the  structural  details  of  the 
aforementioned loop structure on account of these 
concerns,  even  though  desolvation  of  Asp23  is 
seen  experimentally in  the  NMR structures  (86) 
and in explicit solvent simulations (87) of similar 
fragments. It is worthwhile to point out that in our 
simulations the statistical weight of the loop never 
exceeds  20%  meaning  that  most  computed 
ensemble  averages  would  only  be  moderately 
affected.
Comparison with NMR NOE data. Aside from 
keeping the project computationally tractable, an 
added  motivation  for  studying  the  specific 
fragment  Aβ12-28 was  the  availability  of  NMR 
spectroscopic  data  in  the  presence  of  different 
inhibitors.  For  the  inhibitor  Tyr-Aib-Trp-Phe, 
Frydman-Marom et al. report a few intermolecular 
NOEs  indicating  preferential  binding  of  Aib  to 
residues  20-22  (76).  Undoubtedly,  this  is 
qualitatively compatible with our data as presented 
in Fig. 4. For Aβ12-28 in the presence of NQTrp (4:1 
excess of Aβ12-28), Scherzer-Attali et al. (43) report 
8  long-range  NOEs.  Four  of  them  cover  a 
sequence spacing of only  i,i+4, and five of them 
involve Val18. However, with the exception of an 
NOE  between  the  α-proton  of  Asp23  and  the 
backbone amide proton of Gln15, all of them are 
weak.  When  computing  predicted  NOEs  from 
simulation data, we found a significant number of 
long-range NOEs that should have been detectable 
by NMR irrespective of whether we use 3rd or 6th 
power  averaging  (88).  This  presence  of  "false 
positives" indicates either incompatible ensembles, 
NMR-intrinsic  issues  when  studying  disordered 
systems,  e.g.,  issues pertaining to the lifetime of 
conformational states (89), or inapplicability of the 
model  used for prediction,  considering that most 
hydrogen positions had to be modeled a posteriori. 
Coupled to the fact that the source of NOE signals 
at a 4:1 excess concentration of Aβ12-28 can hardly 
be expected to delineate Aβ-intrinsic and inhibitor-
induced signals,  we  conclude  that  a  quantitative 
comparison  between  measured  NMR parameters 
and  simulation  data  carries  more  caveats  than 
potential. This is particularly true given the lack of 
reliable  long-range  NOEs  observed  for  Aβ12-28 
alone (77).
Structural  ensembles  derived  from  NMR  data 
suggest that Aβ12-28 adopts loop-like or hairpin-like 
structures devoid of canonical backbone hydrogen 
bonds  (40,43),  and  this  trend  is  indirectly 
supported  by  independent  studies  on  different 
fragments  (86,90,91).  Interestingly,  the 
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Disordered binding of small molecules to Aβ12-28
aforementioned loop state that is stabilized in the 
presence of inhibitors features a prominent contact 
between residues Gln15 and Asp23 (see Fig. 4). In 
our simulations, it is however the amide hydrogens 
of  the  glutamine  side  chain  that  mediate  this 
contact (see Fig. 7B). Lastly, due to the very weak 
impact  of  inhibitors  on  average  secondary 
structure  populations  (see  Fig.  6),  we  do  not 
attempt  to  correlate  those  changes  to  chemical 
shift  differences  observed  in  the  presence  of 
inhibitors. 
CONCLUSIONS
The FACTS implicit  solvation model allowed 
us to obtain data with statistical errors that permit 
establishing subtle, quantitative effects of inhibitor 
binding (for example, Fig. 6). Therefore, five main 
results  emerge from the  comparative  analysis  of 
MD  simulations  of  Aβ12-28 alone  and  in  the 
presence of small molecules that have been shown 
experimentally to interfere with Aβ peptide self-
assembly.
1. The  free  energy  surface  of  Aβ12-28 shows  a 
broad entropic basin devoid of a predominant 
conformation  (Fig.  3  and  Figs.  S1-S11  in 
Supplemental  Data).  Upon  inhibitor  binding, 
significant,  but  subtle  changes  to  the  free 
energy  landscape  occur  as  exemplified  by 
changes  in  average  secondary  structure 
propensities and intramolecular contacts (Figs. 
4 and 6). 
2. Different  inhibitors  share  common 
intermolecular  interactions  but  none  of  them 
exhibits a specific binding mode irrespective of 
binding affinity (Table 1 and Fig. 4).
3. Differences  in  affinity  can  be  partially 
rationalized by the relative number of aromatic 
groups  and  charged  groups  in  the  inhibitors 
(Table  1).  The  former  provide  a  favorable 
contribution through hydrophobic interactions 
mainly  with  Phe19  and  Phe20  and  through 
mixed  polar  and  nonpolar  interactions  with 
residues  13-18.  The  desolvation  of  charged 
groups is generally unfavorable,  i.e., inhibitor 
binding does not rely on salt bridge formation 
(Figs. 4 and 5). 
4. The simulation data demonstrate that detailed 
predictions  of  interactions  at  the  molecular 
level cannot just rely on simple heuristics (92). 
As an example, the relative binding properties 
of  the  different  endomorphin  variants  appear 
nearly  impossible  to  rationalize  with  purely 
sequence-based approaches (Table 1). 
5. The data show how small molecules composed 
of similar building blocks can incur a generic 
interfacial effect. Such effect is the cause of the 
enhancement of a specific loop conformation 
of  Aβ12-28 (Table  S1  and  Fig.  S13  in 
Supplemental Data). 
Taken together, the results show how aggregation 
inhibitors can have subtle,  but  significant  effects 
on the behavior of a fragment of Aβ encompassing 
the CHC that  is  most  commonly implied in  the 
peptide's amyloidogenicity. It is important to ask 
whether  our  results  could  apply  to  other 
aggregation-prone  IDPs  as  well.  We  use  α-
synuclein, the disease protein of Parkinson's, as an 
example, which is significantly larger than Aβ, and 
adopts  more  extended conformations  in  solution 
(93).  Despite  large  differences  in  sequence 
properties,  monomeric  ensembles,  and  oligomer 
distributions,  there  exists  a  comparable  range  of 
compounds  possessing  one  or  more  aromatic 
moieties that have been shown to bind monomeric 
α-synuclein (94), and to interfere with α-synuclein 
aggregation  (53,95-98) and  oligomerization 
(99,100). It is not necessary and perhaps unlikely 
that  all  these inhibitors act  in equivalent  fashion 
for  diverse  systems.  Returning  to  Fig.  1,  this 
means  for  example  that  the  multiple  equilibria 
involving inhibitor binding may not all contribute 
significantly. As an example, our data for  β-Ala-
His  suggest  that  this  compound  is  unlikely  to 
interfere  with  Aβ dimerization  at  the  low 
concentrations typically in use  in vitro. Similarly, 
DTrp-Aib exhibited no significant effects on early 
oligomer  formation  of  Αβ1−42 at  concentration 
ratios of up to 40:1 excess of DTrp-Aib (40), and is 
also  largely  unbound  in  our  simulations.  This 
suggests a specific role in step VI for those two 
compounds.  Conversely,  evidence  for  generic 
effects at the oligomer level (in particular step V in 
Fig. 1) is not only given in the wider context of 
enzyme  activity  assays  (101) but  has  also  been 
proposed specifically in the context of aggregation 
experiments (102).
Finally, the consistency between simulation results 
and  experimental  data  (NMR  spectroscopy 
analysis  of  Aβ12-28 and  characterization  of 
inhibition of Aβ40 aggregation) suggest that several 
of the conclusions are independent of the details of 
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Disordered binding of small molecules to Aβ12-28
the simulation model. Encouraged by these results, 
we are currently using the same methodology to 
perform  a  medium-throughput  screening  of  a 
novel class of compounds meant to interfere with 
Aβ oligomerization and fibrillization.
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Disordered binding of small molecules to Aβ12-28
FIGURE LEGENDS
Fig.  1. Schematic  depicting  the  coupled  equilibria  that  could  be  involved  in  inhibition  of 
fibrillization and/or oligomerization of  Aβ  by  small  molecules.  Largely unstructured  peptides  are 
shown as gray ribbons with the CHC highlighted in yellow. Peptides in fibril-compatible conformations  
are shown in red, and inhibitor molecules in blue. Angular brackets indicate conformational equilibria at 
different assembly levels, and curly brackets a repeating unit replicated along the indicated axis. Steps I 
and  II  pertain  to  the  unperturbed,  nucleation-dependent  aggregation  pathway.  On-  and  off-pathway 
assembly steps beyond the dimer are not shown explicitly. Steps VII and VIII are the analogous steps with 
inhibitor bound to the aggregating peptides. Finally, steps III-VI describe binding equilibria to various  
peptide  species.  Preferential  interactions  of  the  CHC  with  inhibitor  molecules  containing  aromatic 
moieties have been postulated (81). See text for further details.
Fig. 2. Average polymeric properties for Aβ12-28 alone and in the presence of various inhibitors. 
Indicated errors are minimum and maximum values obtained from partitioning the data into six blocks.  
Panel  A shows  the  average  atom-to-atom distance  for  pairs  of  residues  as  a  function  of  sequence  
separation. Capping groups are included as separate residues in this analysis. Collapsed globules would 
be indicated by the internal distance reaching a plateau value for sequence spacings beyond the length  
scale  of  local  rigidity.  Random  coil-like  (good  solvent)  chains  are  significantly  more  extended  as  
indicated by the black, dotted line [data from simulation of Aβ12-28 in the excluded volume limit (103)]. 
Panel B shows the angular correlation function of N→C vectors as a function of sequence separation. 
Negative values indicate the chain turning on itself, i.e., (partial) collapse. A good solvent chain leads to 
simple, monotonous decay of the correlation function (black dotted line).
Fig.  3. Monomeric  Aβ 12-28 is  mainly  unstructured. (Top)  DSSP analysis  of  the  sampling  arranged 
according to the reaction coordinate of the cFEP (the color-code is: helix in red; β-extended in green; loop 
and turn in blue; bend is the DSSP letter S and is plotted in yellow for clarity). (Bottom) The cFEP of  
monomeric Aβ12-28 using its most populated conformer as the reference state (the value of the reaction  
coordinate is zero for the reference state). Representative conformations of individual free-energy basins 
are reported as insets (residues 14-24 are highlighted in yellow in the cartoons).
Fig.  4. Intra-  and  intermolecular contact  maps  of  Aβ 12-28 alone  and in  the  presence  of  various 
inhibitors. The color legend applies to all panels. Axes are labeled with single-letter amino acids codes. 
"B" stands for β-alanine, "DT" for DTrp, "NQ" for naphtoquinone, "Z" for α-aminoisobutyric acid (Aib), 
"AC"  for  anthracene,  and  "AQ"  for  anthraquinone.  Capping  groups  for  peptides  are  considered  as 
separate  residues,  but  are  not  labeled  on  the  axes.  A contact  is  defined  as  any  two  atoms  of  the 
corresponding residues being separated by less than 5.5 Å. The diagonal  is excluded.  Upper left  half 
matrices contain average contact probabilities, and lower right half matrices the corresponding standard  
errors estimated as half the difference between the minimum and maximum values measured over six  
blocks.  The region denoted by blue lines shows a specific contact  pattern corresponding to the loop  
structure discussed in the text.
Fig.  5. Matrix of  van der Waals  interaction energy between NQTrp and Aβ 12-28.  The interaction 
energy between individual functional groups of NQTrp and Aβ12-28 residues (backbone and side chain 
atoms) was computed by CHARMM using every 100th snapshot.  NQTrp was decomposed into single 
functional groups with net integer charges (abbreviations CO and CO´, COO-, NH, indole, and NQ stand 
for quinonic carbonyls, carboxy, amide, indole and naphtoquinone moieties, respectively [see Table 1 for 
the chemical  structure of NQTrp]).  The sum of all  pairwise averages reported in the matrix is  -13.3 
kcal/mol.
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Disordered binding of small molecules to Aβ12-28
Fig.  6. Influence  of  different  inhibitors  of  aggregation  on  secondary  structure  propensities  of 
monomeric Aβ 12-28. The secondary structure content was calculated by the DSSPcont algorithm (104) as 
implemented in Wordom (73). (Top) “Loop and turn” are DSSP letters L, S, and T. (Middle) “β-extended” 
consists of DSSP letters E and B. (Bottom) “Helical” are DSSP letters G, H, and I. The error bars indicate 
the range between the maximum and minimum value over three independent 5 µs simulations.
Fig. 7. Helical and  loop conformations identified with cFEP. The helical conformation is shown in 
panel (A). The loop conformation is stabilized by the hydrogen bonds between the side chain of Asp23  
and backbone NH groups as well as the side chains of either Gln15 (B) or His14 (C).
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Disordered binding of small molecules to Aβ12-28
Inhibitor a  Fb to Aβ 12-28 b
Effective Binding Energy
Ref. Structuree
vdW c El c Np c Total d
NQTrp 71 -15.8 4.8 -3.0 -13.9 (43)
9,10-anthraquinone 39 -6.6 2.5 -1.5 -5.6 (37)
anthracene 67 -7.7 1.9 -1.7 -7.5 (37)
Tyr-Aib-Trp-Phe 51 -9.6 3.2 -2.8 -9.2 (76)
Tyr-Pro-Trp-Phe 50 -10.3 3.4 -2.9 -9.8 (76)
Tyr-Pro-Phe-Phe 55 -16.3 4.3 -3.6 -15.6 (76)
Tyr-Pro-Trp-Phe-NH2 62 -11.9 4.1 -3.3 -11.1 /
Tyr-Pro-Phe-Phe-NH2 50 -10.5 3.5 -3.0 -10.0 (105)
DTrp-Aib 19 -4.5 1.8 -1.8 -4.5 (40)
β-Ala-His 10 -0.9 0.9 -0.8 -0.8 (77)
Table 1: Small-molecule inhibitors and their affinity to Aβ 12-28
aAib:  α-aminoisobutyric acid; NQTrp: 1,4-napthoquinon-2-yl-L-tryptophan;  Tyr-Aib-Trp-Phe: designed 
derivative  of  endomorphin-1;  Tyr-Pro-Trp-Phe:  endomorphin-1  with  charged  carboxy  group  at  C-
terminus; Tyr-Pro-Phe-Phe: endomorphin-2 with charged carboxy group at C-terminus; Tyr-Pro-Trp-Phe-
NH2:  endomorphin-1;  Tyr-Pro-Phe-Phe-NH2:  endomorphin-2;  β-Ala-His:  carnosine.  Note  that  the 
endogenous endomorphins have the –NH2 group at the C-terminus. 
bFb is the fraction of snapshots in which any atom of the inhibitor is within 7.5 Å of any atom of Aβ12-28. 
Values are given in percent.
cEach of the these three terms (vdW = van der Waals terms; El = electrostatic interactions; Np = nonpolar  
solvation terms) was calculated by subtracting the energy of Aβ12-28 and inhibitor in the isolated state from 
the energy in the ensemble of bound conformations. 
dThe effective binding energy is the sum of the changes in the van der Waals energy, electrostatic energy,  
and  non-polar  solvation  energy upon binding.  All  values  are  reported  in  kcal/mol.  They include  all  
contributions to the binding free energy except for changes in entropies of the solutes.
eStructure diagrams are omitted for tetrapeptides.
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Figure 1
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Figure 2 
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Figure 3
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Figure 4
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Figure 5
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Disordered binding of small molecules to Aβ12-28
Figure 6
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Figure 7
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Table S1.  Percentage  of molecular  dynamics  snapshots  similar  to the representative  loop conformation 
obtained in the presence of NQTrp using 1.5 Å and 2.0 Å cutoffs in RMSD computed over the Cα atoms of 
residues 14-24.
Inhibitor a
(cutoff 1.5 Å)
3 blocks b 6 blocks b
µ σ MAX min µ σ MAX min
Aβ 12-28 1.8 1.1 2.9 1.0 1.8 1.4 4.2 0.2
NQTrp 19.0 15.3 40.1 4.4 19 17.6 48.7 0.4
9,10-anthraquinone 8.2 6.3 15.5 0.2 8.2 10.8 30.4 0.2
anthracene 5.4 3.6 9.7 0.9 5.4 4.8 11.4 0.3
Tyr-Aib-Trp-Phe 4.5 1.6 6.3 2.4 4.5 4.9 12.5 0.1
Tyr-Pro-Trp-Phe 5.1 2.7 8.9 2.5 5.1 6.3 17.7 0.1
Tyr-Pro-Phe-Phe 5.2 2.4 8.3 2.4 5.2 4.8 14.6 0.2
Tyr-Pro-Trp-Phe-NH2 7.4 3.8 10.9 3.4 7.4 5.8 15.3 0.4
Tyr-Pro-Phe-Phe-NH2 4.3 2.8 7.4 2.1 4.3 3.3 8.0 0.2
DTrp-Aib 6.9 6.5 16.1 1.7 6.9 11.2 31.7 0.2
β-Ala-His 1.4 1.4 3.3 0.1 1.4 1.4 3.8 0.1
Inhibitor a
(cutoff 2.0 Å)
3 blocks b 6 blocks b
µ σ MAX min µ σ MAX min
Aβ12-28 2.9 1.3 4.3 1.6 2.9 1.7 5.5 0.9
NQTrp 22.5 14.0 41.6 8.5 22.5 16.3 50.0 5.4
9,10-anthraquinone 10.3 7.1 18.3 1.1 10.3 11.4 33.3 0.7
anthracene 6.8 3.7 11.1 1.8 6.8 4.4 12.7 2.2
Tyr-Aib-Trp-Phe 6.1 1.5 8.2 4.6 6.1 4.4 14 1.5
Tyr-Pro-Trp-Phe 7.6 3.3 12.2 4.9 7.6 5.4 19.1 3.2
Tyr-Pro-Phe-Phe 16.6 1.1 18.2 15.4 16.6 2.0 20.6 14.3
Tyr-Pro-Trp-Phe-NH2 11.7 2.2 14.1 9.8 11.7 5.7 18.0 1.6
Tyr-Pro-Phe-Phe-NH2 9.9 5.9 16.5 5.1 9.9 8.0 25.3 1.6
DTrp-Aib 8.3 6.9 18.0 2.4 8.3 11.4 33.3 0.7
β-Ala-His 2.2 1.6 4.4 0.6 2.2 1.7 5.5 0.4
aAib: α-aminoisobutyric acid; NQTrp: 1,4-napthoquinon-2-yl-L-tryptophan; β-Ala-His: carnosine. 
bBlock averaging was performed by dividing the 15 µs of total sampling into three 5 µs blocks (left) and six 
2.5 µs blocks (right). µ and σ denote arithmetic mean and standard deviation, respectively, while MAX and 
min are the respective maximum and minimum values for each set of blocks.
2
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on Decem
ber 7, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
Table  S2.  Decomposition  of  effective  binding  energy  into  individual  terms.  All  values  are  given  in 
kcal/mol.
Inhibitor a sampling g vdW b ELEC c FCTPL d FCTNP e TOTAL f
NQTrp
full -15.8 -12.9 17.7 -3.0 -13.9
1st block -15.1 -13.4 18.1 -2.9 -13.4
2nd block -18.4 -15.2 20.3 -3.3 -16.6
3rd block -13.7 -9.9 14.6 -2.8 -11.8
9,10-anthraquinone
full -6.6 -2.9 5.4 -1.5 -5.6
1st block -8.1 -5.4 8.1 -1.7 -6.9
2nd block -6.9 -3.1 5.7 -1.5 -5.9
3rd block -4.9 -0.3 2.6 -1.4 -4.1
anthracene
full -7.7 0.1 1.8 -1.7 -7.5
1st block -8.1 -1.3 3.2 -1.8 -7.9
2nd block -6.1 2.35 -0.6 -1.6 -5.9
3rd block -8.8 -0.77 2.9 -1.9 -4.1
Tyr-Aib-Trp-Phe
full -9.6 -8.8 12.1 -2.8 -9.2
1st block -9.5 -9.5 12.6 -2.8 -9.2
2nd block -8.8 -6.9 10.2 -2.7 -8.3
3rd block -10.5 -10.1 13.4 -2.9 -10.1
Tyr-Pro-Trp-Phe
full -10.3 -10.7 14.1 -2.9 -9.8
1st block -11.5 -13.3 16.8 -3.1 -11
2nd block -9.9 -7.8 10.9 -2.8 -8.5
3rd block -10.3 -11.2 14.5 -2.9 -9.9
Tyr-Pro-Phe-Phe
full -16.3 -14.7 19.1 -3.6 -15.6
1st block -16.9 -16.4 20.6 -3.6 -16.3
2nd block -16.8 -14.7 19.1 -3.7 -15.9
3rd block -15.3 -13.1 17.4 -3.5 -14.5
Tyr-Pro-Trp-Phe-NH2
full -11.9 -5.9 10.0 -3.3 -11.1
1st block -11.9 -7.0 11.1 -3.3 -11.2
2nd block -10.6 -4.3 8.2 -3.1 -9.9
3rd block -13.0 -6.4 10.8 -3.4 -12.0
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Tyr-Pro-Phe-Phe-NH2
full -10.5 -7.0 10.5 -3.0 -10.0
1st block -12.7 -10.1 13.9 -3.3 -12.1
2nd block -7.2 -2.9 5.8 -2.6 -7.0
3rd block -11.2 -7.5 11.2 -3.1 -10.6
DTrp-Aib
full -4.5 -5.5 7.3 -1.8 -4.5
1st block -3.1 -5.5 6.8 -1.6 -3.3
2nd block -3.7 -2.9 4.6 -1.7 -3.6
3rd block -6.8 -8.1 10.3 -2.0 -6.6
β-Ala-His
full -0.9 -4.9 5.7 -0.8 -0.8
1st block -0.5 -4.6 5.3 -0.8 -0.7
2nd block -0.5 -4.7 5.7 -0.7 -0.3
3rd block -1.7 -5.2 6.2 -0.9 -1.5
aAib: α-aminoisobutyric acid;  NQTrp:1,4-napthoquinon-2-yl-L-tryptophan; β-Ala-His: carnosine.
bvdW = van der Waals energy change upon binding
cELEC = low-dielectric Coulombic energy upon binding
dFCTPL = change of electrostatic polarization upon binding calculated by FACTS (Haberthür and Caflisch, 
J Comput Chem, 2008)
eFCTNP  =  change  of  non-polar  solvation  energy  calculated  by  FACTS  using  a  surface  tension-like 
parameter γ = 0.0075 kcal mol-1 Å-2
fTOTAL = the total binding energy is the sum of the four preceding terms
gBlock averaging was performed by dividing the 15 µs sampling into three 5 µs blocks. For further details, 
refer to Table 1 in the main text.
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Figure S1. cFEP and other analyses of monomeric Aβ12-28. The analysis  in  A-D) uses the snapshots 
rearranged  according  to  the  reaction  coordinate  in  E).  A) Root  mean  square  deviation  (RMSD)  of 
monomeric  Aβ12-28 from the cluster  representative of the most populated node of Aβ12-28 in presence of 
NQTrp. B) RMSD of monomeric Aβ12-28 from its most populated conformer. C) Radius of gyration (RGYR) 
of monomeric Aβ12-28. Cα atoms of residues 14-24 were used in RMSD and RGYR analyses.  D) DSSP 
analysis of monomeric Aβ12-28 (the color code is: helix in red; β-extended in green; loop and turn in blue; 
bend is plotted in yellow for clarity). The secondary structure analysis was calculated using the DSSPcont 
algorithm as implemented in Wordom (Seeber  et al.,  J Comput Chem  32,  1183 (2011)).  E) cFEP plots 
starting  from the  most  populated  node  of  the  conformational  network  as  reference.  Nodes  are  sorted 
according to their mean first passage time (mfpt) from the reference structure (for further details see Krivov 
and Karplus, J \Phys Chem B, 110, 12689 (2006)). RMSD clustering over the Cα atoms of residues 14-24 of 
monomeric Aβ12-28 with 1.0 Å (black), 1.5 Å (red), and 2.0 Å (green) cutoffs was used for cFEP analysis.
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Figure S2. cFEP and other analyses of monomeric Aβ12-28  in presence of NQTrp. The analysis in A-D) 
uses the snapshots rearranged according to the reaction coordinate in E). A) RMSD of Aβ12-28 in presence of 
NQTrp from the cluster representative of the most populated node of monomeric Aβ12-28 alone. B) RMSD of 
Aβ12-28 in presence of NQTrp from its most populated conformer. C) Radius of gyration (RGYR) of Aβ12-28 
in presence of NQTrp. Cα  atoms of residues 14-24 were used in RMSD and RGYR analyses.  D) DSSP 
analysis of monomeric Aβ12-28 in presence of NQTrp (the color code is: helix in red;  β-extended in green; 
loop and turn in blue; bend is plotted in yellow for clarity). E) cFEP plots starting from the most populated 
node of the conformational network as reference. Nodes are sorted according to their mean first passage time 
(mfpt) from the reference structure. RMSD clustering over the Cα atoms of residues 14-24 of monomeric 
Aβ12-28 in presence of NQTrp with 1.0 Å (black), 1.5 Å (red), and 2.0 Å (green) cutoffs was used for cFEP 
analysis.
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Figure S3.  cFEP and other analyses of  monomeric Aβ12-28  in  presence of  9,10-anthraquinone.  The 
analysis in  A-D) uses the snapshots rearranged according to the reaction coordinate in  E).  A) RMSD of 
Aβ12-28 in presence of 9,10-anthraquinone from the cluster representative of the most populated node of 
monomeric Aβ12-28 in presence of NQTrp. B) RMSD of Aβ12-28 in presence of 9,10-anthraquinone from its 
most populated conformer. C) Radius of gyration (RGYR) of Aβ12-28 in presence of 9,10-anthraquinone. Cα 
atoms of residues 14-24 were used in RMSD and RGYR analyses. D) DSSP analysis of monomeric Aβ12-28 
in presence of 9,10-anthraquinone (the color code is: helix in red; β-extended in green; loop and turn in blue; 
bend  is  plotted  in  yellow  for  clarity).  E) cFEP  plots  starting  from  the  most  populated  node  of  the 
conformational network as reference. Nodes are sorted according to their mean first passage time (mfpt) 
from the reference structure. RMSD clustering over the Cα atoms of residues 14-24 of monomeric Aβ12-28 in 
presence of 9,10-anthraquinone with 1.0 Å (black), 1.5 Å (red), and 2.0 Å (green) cutoffs was used for cFEP 
analysis.
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Figure S4. cFEP and other analyses of monomeric Aβ12-28 in presence of anthracene. 
Same as Figure S3 for anthracene.
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Figura S5. cFEP and other analyses of monomeric Aβ12-28 in presence of Tyr-Aib-Trp-Phe. 
Same as Figure S3 for Tyr-Aib-Trp-Phe.
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Figure S6. cFEP and other analyses of monomeric Aβ12-28 in presence of Try-Pro-Trp-Phe. 
Same as Figure S3 for Tyr-Pro-Trp-Phe.
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Figure S7. cFEP and other analyses of monomeric Aβ12-28 in presence of Tyr-Pro-Phe-Phe. 
Same as Figure S3 for Tyr-Pro-Phe-Phe.
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Figure S8. cFEP and other analyses of monomeric Aβ12-28 in presence of Tyr-Pro-Trp-Phe-NH2. 
Same as Figure S3 for Tyr-Pro-Trp-Phe-NH2.
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Figure S9. cFEP and other analyses of monomeric Aβ12-28 in presence of Tyr-Pro-Phe-Phe-NH2. 
Same as Figure S3 for Tyr-Pro-Phe-Phe-NH2.
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Figure S10. cFEP and other analyses of monomeric Aβ12-28 in presence of DTrp-Aib. 
Same as Figure S3 for DTrp-Aib.
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Figure S11. cFEP and other analyses of monomeric Aβ12-28 in presence of β-Ala-His. 
Same as Figure S3 for β-Ala-His.
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Figure S12. cFEP plots with the loop conformer as encountered in each simulation as reference state.
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Figure S13.  Time series of  Cα RMSD from the representative node of the most populated cluster in 
simulations of Aβ12-28 in the presence of NQTrp (loop conformer). The Cα atoms of residues 14-24 were 
used to calculate the RMSD. The red dashed line at 1.5 Å is only a guide to the eye.
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Figure S14.  Two-dimensional histograms of the RMSD over Cα atoms of residues 14-24 to a reference 
structure  and site-site  distances  between  inhibitor  and  peptide.  The  chosen reference  structure  was  the 
representative  node of  the most  populated  cluster  for the system in which the loop structure was most 
strongly populated, i.e., Aβ12-28 in the presence of NQTrp. Here, two different inhibitors are analyzed: DTrp-
Aib (left column), and anthracene (right column). The sites on the peptide were the side chain oxygen atoms  
of Asp23 and Gln15. For DTrp-Aib, site-site correlation functions were computed to the polar indole nitrogen 
(lower left) or to the N-terminal, charged nitrogen (upper left). For anthracene, the sites considered were the 
four terminal carbons (lower right), and the two central carbons (upper right). In all cases, the distance axis 
can be used to distinguish bound from unbound states, and the RMSD axis can be used to distringuish loop-
like  from  other  conformations.  Due  to  the  good  separation  between  states,  the  bottom  row  contains 
approximate sums of probabilities in the indicated, rectangular regions. These data indicate that anthracene 
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stabilizes the loop largely by direct interaction, whereas the impact of  DTrp-Aib can also be indirect. The 
latter could be the result of both allosteric and memory effects.
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